Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)

Inclusion Criteria: * Age \> 18 years * Signed informed consent * Subjects refer worsening in their pathologies when exposed to adverse environmental conditions in their daily life * Fluorescein corneal staining ≥ 1in Oxford Scale * Ocular surface disease index (OSDI) test \> 12 * Tear breakup Time (TBT) ≤ 7 seconds in both eyes * Schirmer test without anesthesia ≤ 10 mm in 5 minutes in both eyes * Any concomitant medication that may affect dry eye syndrome, ocular surface or vision, must have started at least 3 months before screening visit, and there are no changes in dose expected during the study duration. * Best corrected visual acuity at least 0.1 logMar at 6 meters with both eyes * Current use of ophthalmic artificial tears at study inclusion. * Signed informed consent * Signed data protection consent Exclusion Criteria: * Sensitivity or known intolerance to any of the products used in the study * Previous severe ocular inflammation or infections in the 6 previous months to study inclusion * Any ocular pathology other than dry eye syndrome or atopic keratoconjunctivitis * Any ocular surgery or trauma that may affect corneal sensitivity and / or normal tear distribution (refractive or cataract surgery) in the 6 previous months or any ocular or systemic surgery planned during the study duration that may affect the study as assessed by principal investigator. * Use of contact lenses in the 3 previous months to study inclusion * Use of any topical medication for pathologies other than dry eye syndrome. * Any ocular topical treatment for dry eye syndrome with corticosteroids or non steroid anti-inflammatory drugs must have stopped 1 month before study inclusion. Any treatment with topical cyclosporin must have been stopped 3 months before study inclusion. * Any uncontrolled severe systemic disease that may affect the eye (except for Sjögren Syndrome) * Start, discontinuation or dose change during the study of antihistaminic, cholinergic agents, beta blockers, antidepressants or any other systemic medications with potential effect over tear film. * Start of any systemic treatment that may affect dry eye syndrome, vision, ocular surface or intraocular pressure during the 3 previous months to study inclusion. * Surgical / non surgical tear point occlusion in the 3 previous months to study inclusion or prevision during study duration for this procedure. * Cup / disc ratio \> 0.6 * History of intraocular pressure \> 22 mm Hg within 2 months previous to study inclusion * Pregnancy or breastfeeding women * Inclusion in another research study in the previous 30 days to study inclusion